Incidence of humoral sensitization in HLA partially mismatched hematopoietic stem cell transplantation

Tissue Antigens

Volumn 74, Issue 6, 2009, Pages 494-498

  Leffell, M S ^a   Cao, K ^b   Coppage, M ^c   Hansen, J A ^d   Hart, J M ^a   Pereira, N ^e   Pereira, S ^d   Reinsmoen, N L ^b   Senitzer, D ^f   Smith, A ^d   Torres, M ^g   Vega, R ^a   Fuchs, E ^h  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e Laboratorio de Imunogenetica   (Brazil)

^f City of Hope Medical Center   (United States)

^g HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^h JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Alloantibodies; Hematopoietic cell transplants; Human leukocyte antigen mismatched transplants; Human leukocyte antigen specific antibodies; Nonmyeloablative hematopoietic cell transplants

Indexed keywords

ANTIBODY SPECIFICITY; BLOOD DONOR; CONFERENCE PAPER; FLUORESCENCE ANALYSIS; GRAFT RECIPIENT; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA MATCHING; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNOGENETICS; INCIDENCE; PRIORITY JOURNAL; SENSITIZATION;

GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; TISSUE DONORS;

EID: 70449331681     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2009.01377.x     Document Type: Conference Paper

References (14)

1. Mielcarel M, Storb R. Nonmyeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies. Cancer Treat Rev 2003 : 29 : 283 290. (Pubitemid 37069658)
2. O′Donnell PV, Luznik L., Jones RJ et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002 : 8 : 377 386.
3. Anasetti C, Amos D, Beatty PG et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Eng J Med 1989 : 320 : 197 204.
4. Ottinger HD, Rebmann V, Pfeiffer KA et al. Positive serum cross-match as predictor for graft failure in HLA-mismatched allogeneic blood stem cell transplantation. Transplantation 2002 : 73 : 1280 1285.
5. Narimatsu H, Wake A, Miura Y et al. Successful engraftment in crossmatch-positive HLA-mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusion. Bone Marrow Transplant 2005 : 36 : 555 556.
6. Kataoka K, Yamamoto G, Nannya Y et al. Successful engraftment following HLA-mismatched cord blood transplantation for patients with anti-HLA antibodies. Bone Marrow Transplant 2008 : 42 : 129 130.
7. Gutman JA, McKinney SK, Pereira S et al. Prospective monitoring for alloimmunization in cord blood transplantation: "virtual crossmatch" can be used to demonstrate donor-directed antibodies. Transplantation 2009 : 87 : 415 418.
8. Abou-Elella AA, Camarillo TA, Allen MB et al. Low incidence of red cell and HLA antibody formation by bone marrow transplant patients. Transfusion 1995: 35 : 931 935.
9. Gluckman E, Gluckman JC, Andersen E, Devergie A, Dausset J. Lymphocytotoxic antibodies and bone marrow grafts from HLA-identical siblings. I. HLA antibodies. Transplantation 1978 : 26 : 284 286.
10. Lapierre V, Aupérin A, Tayebi H et al. Increased presence of anti-HLA antibodies early after allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood hematopoietic stem cell transplantation compared with bone marrow transplantation. Blood 2002 : 100 : 1484 1489.
11. Geiger TL, Woodward P, Tong X et al. Human leucocyte alloimmunization after bone marrow transplantation: an association with chronic myelogenous leukaemia. Br J Hematol 2002 : 117 : 643 641.
12. Luznik L, O′Donnell PV, Symons HJ et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Bone Marrow Transplant 2008 : 14 : 641 650.
13. Zachary AA, Sholander JT, Houp JA, Leffell MS. Using real data for a virtual crossmatch. Human Immunol 2009 : 70 : 574 579.
14. Kasamon YL, Leffell MS, Kowalski J et al. Greater HLA disparity is associated with reduced risk of relapse and improved event-free survival after nonmyeloablative, HLA-haploidentical BMT with post-transplantation high-dose cyclophosphamide. Blood 2008 : 112 : 150.